Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Riss, D; Burian, M; Wolf, A; Kranebitter, V; Kaider, A; Arnoldner, C.
Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial.
Head Neck. 2015; 37(6):783-787
Doi: 10.1002/hed.23655
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Wolf Axel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The purpose of this study was to investigate the efficacy of bevacizumab ("Avastin") for the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT). In this double blind, placebo controlled trial, 15 adult patients with HHT with a minimum of 2 epistaxis episodes per week were randomized. A history of thromboembolic events or recent or planned surgery led to exclusion. Patients received a single intranasal submucosal injection (10 mL) of 100 mg bevacizumab or placebo. The primary outcome was the relative reduction of average daily epistaxis visual analog score (VAS). Average daily posttreatment VAS scores decreased by 27% in the bevacizumab group and by 3% in the placebo group (p = .57). The reduction in HHT epistaxis severity scores was -0.61 greater in the bevacizumab group compared to the placebo group (p = .34). Results show a trend toward reduced epistaxis with bevacizumab. This further supports the use of bevacizumab in HHT. Clincial Trials. gov number: NCT01314274 © 2014 Wiley Periodicals, Inc.
- Find related publications in this database (using NLM MeSH Indexing)
- Administration, Intranasal -
- Adolescent -
- Adult -
- Aged -
- Aged, 80 and over -
- Aged, 80 and over -
- Bevacizumab - administration & dosage
- Double-Blind Method -
- Epistaxis - drug therapy
- Epistaxis - etiology
- Female -
- Follow-Up Studies -
- Humans -
- Injections, Intralesional -
- Male -
- Middle Aged -
- Nasal Mucosa - drug effects
- Pain Measurement -
- Risk Assessment -
- Severity of Illness Index -
- Telangiectasia, Hereditary Hemorrhagic - complications
- Telangiectasia, Hereditary Hemorrhagic - diagnosis
- Treatment Outcome -
- Young Adult -
- Find related publications in this database (Keywords)
- Rendu-Osler-Weber syndrome
- hereditary hemorrhagic telangiectasia (HHT)
- avastin